Related Experiment Video
Updated: Oct 10, 2025
10:16
Author Spotlight: Development of Simplified CRISPR-Based Tests for Rapid Detection of Infectious Diseases
Published on: August 16, 2024
1.5K
Instrument-free, CRISPR-based diagnostics of SARS-CoV-2 using self-contained microfluidic system
Ziyue Li1, Xiong Ding2, Kun Yin2
1Department of Biomedical Engineering, University of Connecticut Health Center, 263 Farmington Ave., Farmington, CT, 06030, United States; Department of Biomedical Engineering, University of Connecticut, 260 Glenbrook Road, Storrs, CT, 06029, United States.
Biosensors & Bioelectronics
|December 15, 2021
Summary
A new CRISPR-based diagnostic tool offers rapid, instrument-free detection of SARS-CoV-2 (the virus causing COVID-19). This affordable microfluidic system provides sensitive and accurate results at the point of care.
Area of Science:
- Biotechnology
- Molecular Diagnostics
- Medical Devices
Background:
- Accurate detection of SARS-CoV-2 is crucial for managing COVID-19.
- Existing diagnostic methods often require complex, expensive equipment, limiting point-of-care applications.
- There is a need for simple, sensitive, and affordable diagnostic tools for widespread use.
Purpose of the Study:
- To develop a simple, sensitive, and instrument-free diagnostic method for SARS-CoV-2 detection.
- To integrate multiple steps of nucleic acid detection into a single, closed microfluidic system.
- To create an affordable and portable diagnostic tool for point-of-care use.
Main Methods:
- Development of a self-contained microfluidic chip integrating isothermal amplification, CRISPR cleavage, and lateral flow detection.
- Lyophilization of CRISPR reagents and pre-storage of solutions for simplified operation and transport.
- Utilization of a portable hand warmer for electrical-free incubation.
- Clinical validation using nasopharyngeal swab samples.
Main Results:
- The microfluidic system achieved contamination-free, visual detection of SARS-CoV-2.
- The limit of detection was as low as 100 copies of SARS-CoV-2 RNA.
- Clinical validation demonstrated high sensitivity (94.1%), specificity (100%), and accuracy (95.8%).
Conclusions:
- The developed CRISPR-based microfluidic system offers a simple, sensitive, and affordable solution for SARS-CoV-2 diagnostics.
- This instrument-free approach is suitable for point-of-care applications.
- The technology holds promise for diagnosing COVID-19 and other infectious diseases efficiently.
